G. Cserni, R. Bori, I. Sejben, A. Vörös, L. Kaiser et al., Unifocal, multifocal and diffuse carcinomas: A reproducibility study of breast cancer distribution, Breast, vol.22, pp.34-38, 2013.

T. Tot and G. Pekár, Multifocality in "basal-like" breast carcinomas and its influence on lymph node status, Ann. Surg. Oncol, vol.18, pp.1671-1677, 2011.

S. P. Lynch, X. Lei, L. Hsu, F. Meric-bernstam, T. A. Buchholz et al., Breast cancer multifocality and multicentricity and locoregional recurrence, Oncologist, vol.18, pp.1167-1173, 2013.

R. Salgado, P. Aftimos, C. Sotiriou, and C. Desmedt, Evolving paradigms in multifocal breast cancer, Semin. Cancer Biol, vol.31, pp.111-118, 2015.

B. Manavathi, O. Dey, V. N. Gajulapalli, R. S. Bhatia, S. Bugide et al., Derailed estrogen signaling and breast cancer: An authentic couple, Endocr. Rev, vol.34, pp.1-32, 2013.

Z. Lang, Y. Wu, C. Li, X. Li, X. Wang et al., Multifocal and Multicentric Breast Carcinoma: A Significantly More Aggressive Tumor than Unifocal Breast Cancer, Anticancer Res, vol.37, pp.4593-4598, 2017.

F. E. Vera-badillo, M. Napoleone, A. Ocana, A. J. Templeton, B. Seruga et al., Effect of multifocality and multicentricity on outcome in early stage breast cancer: A systematic review and meta-analysis, Breast Cancer Res. Treat, vol.146, pp.235-244, 2014.

M. Boros, S. Voidazan, C. Moldovan, R. Georgescu, C. Toganel et al., Clinical implications of multifocality as a prognostic factor in breast carcinoma-A multivariate analysis study comprising 460 cases, Int. J. Clin. Exp. Med, vol.8, pp.9839-9846, 2015.

T. M. Weissenbacher, M. Zschage, W. Janni, U. Jeschke, T. Dimpfl et al., Multicentric and multifocal versus unifocal breast cancer: Is the tumor-node-metastasis classification justified?, Breast Cancer Res. Treat, vol.122, pp.27-34, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00612984

T. Weissenbacher, E. Hirte, C. Kuhn, W. Janni, D. Mayr et al., Multicentric and multifocal versus unifocal breast cancer: Differences in the expression of E-cadherin suggest differences in tumor biology, BMC Cancer, vol.13, 2013.

B. Park, K. Kim, M. Heo, S. Ko, S. W. Hong et al., Expression of estrogen receptor-beta in normal mammary and tumor tissues: Is it protective in breast carcinogenesis?, Breast Cancer Res. Treat, vol.80, pp.79-85, 2003.

B. Park, K. Kim, M. Heo, W. Yang, S. I. Kim et al., The changes of estrogen receptor-beta variants expression in breast carcinogenesis: Decrease of estrogen receptor-beta2 expression is the key event in breast cancer development, J. Surg. Oncol, vol.93, pp.504-510, 2006.

T. B. Doan, N. A. Eriksson, D. Graham, J. W. Funder, E. R. Simpson et al., Breast cancer prognosis predicted by nuclear receptor-coregulator networks, Mol. Oncol, vol.8, pp.998-1013, 2014.

V. Cavaillès, S. Dauvois, F. Horset, G. Lopez, S. Hoare et al., Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor, EMBO J, vol.14, pp.3741-3751, 1995.

I. Gurevich, A. M. Flores, and B. J. Aneskievich, Corepressors of agonist-bound nuclear receptors, Toxicol. Appl. Pharmacol, vol.223, pp.288-298, 2007.

A. Docquier, P. Harmand, S. Fritsch, M. Chanrion, J. Darbon et al., The transcriptional coregulator RIP140 represses E2F1 activity and discriminates breast cancer subtypes, Clin. Cancer Res, vol.16, pp.2959-2970, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00482822

J. Lei, R. Peng, B. Kuang, Z. Yuan, T. Qin et al., NOP14 suppresses breast cancer progression by inhibiting NRIP1/Wnt/?-catenin pathway, Oncotarget, vol.6, pp.25701-25714, 2015.

M. Lapierre, A. Docquier, A. Castet-nicolas, D. Gitenay, S. Jalaguier et al., The emerging role of the transcriptional coregulator RIP140 in solid tumors, Biochim. Biophys. Acta, vol.1856, pp.144-150, 2015.
URL : https://hal.archives-ouvertes.fr/hal-02316634

P. Augereau, E. Badia, S. Carascossa, A. Castet, S. Fritsch et al., The nuclear receptor transcriptional coregulator RIP140, Nucl. Recept. Signal, 2006.

A. Docquier, A. Garcia, J. Savatier, A. Boulahtouf, S. Bonnet et al., Negative regulation of estrogen signaling by ER? and RIP140 in ovarian cancer cells, Mol. Endocrinol, vol.27, pp.1429-1441, 2013.

S. C. Ruddy, R. Lau, M. A. Cabrita, C. Mcgregor, B. C. Mckay et al., Preferential estrogen receptor ? ligands reduce Bcl-2 expression in hormone-resistant breast cancer cells to increase autophagy, Mol. Cancer Ther, vol.13, pp.1882-1893, 2014.

Z. Madak-erdogan, T. Charn, Y. Jiang, E. T. Liu, J. A. Katzenellenbogen et al., Integrative genomics of gene and metabolic regulation by estrogen receptors ? and ?, and their coregulators, Mol. Syst. Biol, vol.9, 2013.

J. Nautiyal, J. H. Steel, M. R. Mane, O. Oduwole, A. Poliandri et al., The transcriptional co-factor RIP140 regulates mammary gland development by promoting the generation of key mitogenic signals, vol.140, pp.1079-1089, 2013.

I. Fernandes, Y. Bastien, T. Wai, K. Nygard, R. Lin et al., Ligand-dependent nuclear receptor corepressor LCoR functions by histone deacetylase-dependent and -independent mechanisms, Mol. Cell, vol.11, pp.139-150, 2003.

Y. Song, S. Shan, Y. Zhang, W. Liu, W. Ding et al., Ligand-dependent corepressor acts as a novel corepressor of thyroid hormone receptor and represses hepatic lipogenesis in mice, J. Hepatol, vol.56, pp.248-254, 2012.

M. Asim, B. B. Hafeez, I. A. Siddiqui, C. Gerlach, M. Patz et al., Ligand-dependent corepressor acts as a novel androgen receptor corepressor, inhibits prostate cancer growth, and is functionally inactivated by the Src protein kinase, J. Biol. Chem, vol.286, pp.37108-37117, 2011.

S. Jalaguier, C. Teyssier, T. Nait-achour, A. Lucas, S. Bonnet et al., Complex regulation of LCoR signaling in breast cancer cells, vol.36, pp.4790-4801, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02294843

S. Sixou, K. Müller, S. Jalaguier, C. Kuhn, N. Harbeck et al., Importance of RIP140 and LCoR Sub-Cellular Localization for Their Association With Breast Cancer Aggressiveness and Patient Survival, Transl. Oncol, vol.11, pp.1090-1096, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02292304

A. M. Shaaban, A. R. Green, S. Karthik, Y. Alizadeh, T. A. Hughes et al., Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients, Clin. Cancer Res, vol.14, pp.5228-5235, 2008.

M. Yan, M. Rayoo, E. A. Takano, and S. B. Fox, Nuclear and cytoplasmic expressions of ER?1 and ER?2 are predictive of response to therapy and alters prognosis in familial breast cancers, Breast Cancer Res. Treat, vol.126, pp.395-405, 2011.

E. K. Shanle, A. A. Onitilo, W. Huang, K. Kim, C. Zang et al., Prognostic significance of full-length estrogen receptor beta expression in stage I-III triple negative breast cancer, Am J. Transl. Res, vol.7, pp.1246-1259, 2015.

G. V. Dall, S. Hawthorne, Y. Seyed-razavi, J. Vieusseux, W. Wu et al., Estrogen receptor subtypes dictate the proliferative nature of the mammary gland, J. Endocrinol, vol.237, pp.323-336, 2018.

T. Kim, A. Lee, Y. Choi, B. J. Song, H. W. Yim et al., Prognostic Significance of High Expression of ER-beta in Surgically Treated ER-Positive Breast Cancer Following Endocrine Therapy, J Breast Cancer, vol.15, pp.79-86, 2012.

L. Guo, Q. Zhu, D. Yilamu, A. Jakulin, S. Liu et al., Expression and prognostic value of estrogen receptor beta in breast cancer patients, Int. J. Clin. Exp. Med, vol.7, pp.3730-3736, 2014.

W. Tan, Q. Li, K. Chen, F. Su, E. Song et al., Estrogen receptor beta as a prognostic factor in breast cancer patients: A systematic review and meta-analysis, Oncotarget, vol.7, pp.10373-10385, 2016.

E. W. Elston and I. O. Ellis, Method for grading breast cancer, J. Clin. Pathol, vol.46, pp.189-190, 1993.

I. Mylonas, J. Makovitzky, U. Jeschke, V. Briese, K. Friese et al., Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone, Anticancer Res, vol.25, pp.1719-1723, 2005.

C. Bock, C. Kuhn, N. Ditsch, R. Krebold, S. Heublein et al., Strong correlation between N-cadherin and CD133 in breast cancer: Role of both markers in metastatic events, J. Cancer Res. Clin. Oncol, vol.140, pp.1873-1881, 2014.